This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Randomized, Double-Blinded, Placebo-Controlled Trial of Laxatives for Children With Urge Syndrome

Expanded access is currently available for this treatment.
Verified October 2008 by University of Texas Southwestern Medical Center
Sponsor:
Information provided by:
University of Texas Southwestern Medical Center
ClinicalTrials.gov Identifier:
NCT00765557
First received: September 30, 2008
Last updated: October 2, 2008
Last verified: October 2008
  Purpose

We hypothesize fecal retention is the primary source of bladder dysfunction in some children with Urge Syndrome. Our specific aims are:

  1. To test this hypothesis through a prospective, randomized, double-blinded and placebo-controlled trial of laxatives for children diagnosed with US.
  2. To determine if a validated questionnaire of bowel activity administered to the family, and when appropriate, the patient, will identify those likely to benefit from laxative therapy for bladder dysfunction.
  3. To determine if the abdominal X-Ray of the kidneys, ureters and bladder (KUB) assessment of fecal loading corresponds to answers on the questionnaire regarding incidence of constipation, and/or response to laxative therapy for US.

Condition Intervention
Urge Syndrome Drug: Miralax

Study Type: Expanded Access     What is Expanded Access?
Official Title: Randomized, Double-Blinded, Placebo-Controlled Trial of Laxatives for Children With Urge Syndrome

Further study details as provided by University of Texas Southwestern Medical Center:

Intervention Details:
    Drug: Miralax
    Every subject will be given one bottle of the laxative/placebo, and depending on the patient's weight, will be instructed to take 1-3 tsps (.75 gm/kg) of the medication daily.
  Eligibility

Ages Eligible for Study:   4 Years to 21 Years   (Child, Adult)
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  • Toilet-trained with a history of urinary tract infection; vesicoureteral reflux; urinary incontinence; daily frequency and urgency; and diurnal incontinence.

Exclusion Criteria:

  • Children who are below 4 years old as they may still not be toilet-trained; children with encopresis; children with anorectal malformations; and children with neurologic disorders.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00765557

Contacts
Contact: Warren T Snodgrass, M.D. 214-456-2483 Warren.Snodgrass@childrens.com

Sponsors and Collaborators
University of Texas Southwestern Medical Center
  More Information

Responsible Party: Warren T. Snodgrass, M.D., University of Texas Southwestern Medical School
ClinicalTrials.gov Identifier: NCT00765557     History of Changes
Other Study ID Numbers: 122004-038
Study First Received: September 30, 2008
Last Updated: October 2, 2008

Keywords provided by University of Texas Southwestern Medical Center:
To determine if laxative therapy can resolve Urge Syndrome, and if so, in which patients.
To determine usefulness of KUB, an abdominal X-ray of the kidneys, ureters, and bladder.
To predict the bowel activity of children with Urge Syndrome, who are most likely to respond to laxatives, with the use of the Bowel/Bladder questionnaire.

Additional relevant MeSH terms:
Syndrome
Disease
Pathologic Processes
Laxatives
Cathartics
Gastrointestinal Agents

ClinicalTrials.gov processed this record on August 16, 2017